Through OneOncology, we will be able to identify best practices and support patients throughout the continuum of care, explained Jeff Patton, MD, chief executive officer of Tennessee Oncology.
Through OneOncology, we will be able to identify best practices and support patients throughout the continuum of care, explained Jeff Patton, MD, chief executive officer of Tennessee Oncology.
Transcript
How will partnerships through OneOncology better help community practices support patients throughout the entire continuum of care?
We’re going to use best practices from our best practices, is 1. Number 2, we’ve all learned a lot about how to provide better care to patients in the Oncology Care Model. I think focusing on the patient experience throughout the continuum of care is something we’re really focused on, but it really is identifying best practices and then communicating that across the network. It’s one of the secret sauces of what we’re building at OneOncology.
What do you think the future holds for OneOncology?
I’m excited about the future, and so, change is opportunity as far as I’m concerned and we’re concerned. That’s why we started OneOncology. We founded OneOncology so that we can impact the future, hopefully build a network across the nation that will change the way cancer care is delivered in the country
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More